Raphas라파스
214260 · KOSDAQ · ₩214260 · 라파스
- Market cap
- ₩61B
- Enterprise value
- ₩77B
- P/E
- —
- P/B
- 2.4×
- Dividend yield
- 0.0%
- ROE
- −21.4%
- Net margin
- −18.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−58.8% from the high
₩6,240Today: ₩6,750 – ₩7,030₩16,670
Returns
- 1W−2.6%
- 1M−8.8%
- 3M−14.9%
- 6M−27.8%
- YTD−47.6%
- 1Y−49.1%
- Volume today
- 8,007
- 1.0× the 20-day average
- Traded today
- ₩55M
- Listed shares
- 8,922,463
- EPS (12 months)
- −₩614
- Earnings yield −9.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumWeak-10% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Raphas stock overview
Raphas (라파스, KRX: 214260) is listed on KOSDAQ, in the Cosmetics sector. Raphas develops, manufactures and sells dissolving microneedle patches based on its proprietary DEN (Droplet extension) transdermal drug delivery technology. Its shares closed at ₩6,860 on Oct 29, 2026, down 2.56% on the day, giving it a market value of ₩61B.
Key facts
- Market cap
- ₩61B
- Sector
- Cosmetics
- Latest price change
- −2.56%
- As of
- Oct 29, 2026
- Main business
- Raphas develops, manufactures and sells dissolving microneedle patches based on its proprietary DEN (Droplet extension) transdermal drug delivery technology.
Quick answers about Raphas
- What does Raphas do?
- Raphas develops, manufactures and sells dissolving microneedle patches based on its proprietary DEN (Droplet extension) transdermal drug delivery technology. Its revenue currently comes mainly from cosmetic patches such as beauty patches, and it is expanding into over-the-counter and prescription drug patches, vaccine patches and medical devices, including the Terapass drug absorption aid. The company operates in Korea and sells overseas, including in the United States, Japan and Europe.
- What is the market cap of Raphas?
- The market capitalisation of Raphas was ₩61B at the close on Oct 29, 2026.
- Who are the largest shareholders of Raphas?
- According to the latest official filings, the largest reported holders are Jeong Do-hyeon (20.61%, as of May 12, 2026); National Pension Service (0.90%, as of Dec 31, 2019); Ha Gi-wan (0.01%, as of Jun 2, 2026).
- When is the next earnings report from Raphas?
- Korean companies rarely announce results dates in advance. Based on when Raphas filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Raphas?
- Yes. The National Pension Service held 0.90% of Raphas shares as of Dec 31, 2019.
Company profile
Raphas develops, manufactures and sells dissolving microneedle patches based on its proprietary DEN (Droplet extension) transdermal drug delivery technology. Its revenue currently comes mainly from cosmetic patches such as beauty patches, and it is expanding into over-the-counter and prescription drug patches, vaccine patches and medical devices, including the Terapass drug absorption aid. The company operates in Korea and sells overseas, including in the United States, Japan and Europe.
Written by AI from the company's latest annual report.
- Korean name
- 라파스
- Sector
- Cosmetics
- Themes
- K-beautyObesity drugs
- CEO
- 정도현
- Founded
- Mar 2006
- Listed
- Nov 2019
- Listed shares
- 8,922,463
- Fiscal year ends
- Month 12
- Website
- www.raphas.com
Similar companies
- APR278470 · ₩11T₩282,500−2.25%
- Amorepacific090430 · ₩7.3T₩124,400−0.08%
- LG H&H051900 · ₩3.8T₩254,000−1.93%
- Cosmax192820 · ₩2.8T₩248,000−4.80%
- Kolmar Korea161890 · ₩2.7T₩115,300−1.87%
- d'Alba Global483650 · ₩1.8T₩144,500−2.17%
- Amorepacific Holdings002790 · ₩1.8T₩23,6500.00%
- Cosmecca Korea241710 · ₩1.1T₩99,000−3.88%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJun 2, 2026
- Amended: Major management matter relevant to investorsMay 28, 2026
- Major management matter relevant to investorsMay 22, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: Raphas / 라파스 / 214260 / KRX:214260
Source: KRX statistical information